* **aTyr Pharma** and **Kyorin** terminated their collaboration agreement effective **July 30, 2026**, according to an SEC filing. * aTyr Pharma said it regains **exclusive global rights to efzofitimod**.
ATYR•ATYR•ATYR•ATYR•
